Ryvu Therapeutics SA (RVU) - Net Assets

Latest as of March 2026: zł41.33 Million PLN ≈ $11.37 Million USD

Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has net assets worth zł41.33 Million PLN (≈ $11.37 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł200.96 Million ≈ $55.31 Million USD) and total liabilities (zł159.63 Million ≈ $43.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RVU strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	zł41.33 Million
% of Total Assets	20.56%
Annual Growth Rate	29.28%
5-Year Change	-58.24%
10-Year Change	26.99%
Growth Volatility	196.95

Ryvu Therapeutics SA - Net Assets Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Ryvu Therapeutics SA market capitalisation.

Annual Net Assets for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual net assets of Ryvu Therapeutics SA from 2010 to 2025. Also explore net asset growth rate of Ryvu Therapeutics SA to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	zł70.75 Million ≈ $19.47 Million	-50.83%
2024-12-31	zł143.88 Million ≈ $39.60 Million	-44.57%
2023-12-31	zł259.59 Million ≈ $71.44 Million	-24.40%
2022-12-31	zł343.39 Million ≈ $94.51 Million	+102.68%
2021-12-31	zł169.42 Million ≈ $46.63 Million	-24.27%
2020-12-31	zł223.72 Million ≈ $61.57 Million	+86.81%
2019-12-31	zł119.76 Million ≈ $32.96 Million	-38.54%
2018-12-31	zł194.86 Million ≈ $53.63 Million	+204.49%
2017-12-31	zł64.00 Million ≈ $17.61 Million	+14.87%
2016-12-31	zł55.71 Million ≈ $15.33 Million	+18.84%
2015-12-31	zł46.88 Million ≈ $12.90 Million	+406.61%
2014-12-31	zł9.25 Million ≈ $2.55 Million	+195.78%
2013-12-31	zł3.13 Million ≈ $861.02K	-43.45%
2012-12-31	zł5.53 Million ≈ $1.52 Million	-51.73%
2011-12-31	zł11.46 Million ≈ $3.15 Million	+662.89%
2010-12-31	zł1.50 Million ≈ $413.48K	--

Equity Component Analysis

This analysis shows how different components contribute to Ryvu Therapeutics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 20995894994.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	zł9.25 Million	17.18%
Other Comprehensive Income	zł-262.49 Million	-487.59%
Other Components	zł519.75 Million	965.46%
Total Equity	zł53.83 Million	100.00%

Ryvu Therapeutics SA Competitors by Market Cap

The table below lists competitors of Ryvu Therapeutics SA ranked by their market capitalization.

Company	Market Cap
icad inc NASDAQ:ICAD	$106.31 Million
TCM Group CO:TCM	$106.36 Million
Bogota Financial Corp NASDAQ:BSBK	$106.38 Million
Star Holdings NASDAQ:STHO	$106.47 Million
Kalray SA PA:ALKAL	$106.25 Million
Lhyfe SA PA:LHYFE	$106.24 Million
Forsys Metals Corp. TO:FSY	$106.22 Million
DAM CAPITAL ADVISORS LTD NSE:DAMCAPITAL	$106.20 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ryvu Therapeutics SA's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 143,884,000 to 53,834,000, a change of -90,050,000 (-62.6%).
Net loss of 101,229,000 reduced equity.
Other comprehensive income increased equity by 11,179,001.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	zł-101.23 Million	-188.04%
Other Comprehensive Income	zł11.18 Million	+20.77%
Other Changes	zł-1.00	-0.0%
Total Change	zł-	-62.59%

Book Value vs Market Value Analysis

This analysis compares Ryvu Therapeutics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 7.17x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 116.31x to 7.17x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2010-12-31	zł0.14	zł16.70	x
2011-12-31	zł1.10	zł16.70	x
2012-12-31	zł0.53	zł16.70	x
2013-12-31	zł0.30	zł16.70	x
2014-12-31	zł0.88	zł16.70	x
2015-12-31	zł3.56	zł16.70	x
2016-12-31	zł4.03	zł16.70	x
2017-12-31	zł4.52	zł16.70	x
2018-12-31	zł12.36	zł16.70	x
2019-12-31	zł7.50	zł16.70	x
2020-12-31	zł13.34	zł16.70	x
2021-12-31	zł8.79	zł16.70	x
2022-12-31	zł18.73	zł16.70	x
2023-12-31	zł11.34	zł16.70	x
2024-12-31	zł6.22	zł16.70	x
2025-12-31	zł2.33	zł16.70	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ryvu Therapeutics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -188.04%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -162.61%
• Asset Turnover: 0.28x
• Equity Multiplier: 4.17x
Recent ROE (-188.04%) is below the historical average (-43.08%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	-131.36%	-22.31%	0.86x	6.84x	zł-2.12 Million
2011	-38.73%	-49.22%	0.52x	1.53x	zł-5.58 Million
2012	-116.19%	-68.24%	0.61x	2.77x	zł-6.98 Million
2013	-76.24%	-18.14%	0.73x	5.75x	zł-2.70 Million
2014	63.22%	20.27%	1.08x	2.90x	zł4.92 Million
2015	13.50%	15.28%	0.63x	1.40x	zł1.62 Million
2016	4.91%	5.65%	0.54x	1.61x	zł-2.82 Million
2017	10.28%	7.30%	0.85x	1.66x	zł177.14K
2018	-0.06%	-0.14%	0.30x	1.33x	zł-19.30 Million
2019	-30.06%	-84.57%	0.23x	1.53x	zł-47.97 Million
2020	-14.16%	-205.57%	0.05x	1.32x	zł-54.06 Million
2021	-49.02%	-706.91%	0.05x	1.42x	zł-95.21 Million
2022	-24.40%	-215.91%	0.08x	1.38x	zł-118.12 Million
2023	-35.48%	-196.57%	0.12x	1.55x	zł-118.07 Million
2024	-77.45%	-142.92%	0.21x	2.63x	zł-125.82 Million
2025	-188.04%	-162.61%	0.28x	4.17x	zł-106.61 Million

Industry Comparison

This section compares Ryvu Therapeutics SA's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $117,129,765
Average return on equity (ROE) among peers: -421.91%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Ryvu Therapeutics SA (RVU)	zł41.33 Million	-131.36%	3.86x	$106.26 Million
Bioton S.A. (BIO)	$808.11 Million	11.47%	0.23x	$87.43 Million
Captor Therapeutics S.A. (CTX)	$144.00K	-125.00%	34.58x	$109.92 Million
Mabion S.A. (MAB)	$3.73 Million	-1497.08%	23.47x	$35.18 Million
Molecure S.A. (MOC)	$100.93 Million	-28.11%	0.11x	$43.26 Million
Nanogroup SA (NNG)	$8.37 Million	-119.60%	1.43x	$21.38 Million
Pharmena S.A. (PHR)	$13.08 Million	-31.23%	0.29x	$9.53 Million
PolTREG S.A. (PTG)	$87.52 Million	-15.48%	0.45x	$28.11 Million
Pure Biologics Spólka Akcyjna (PUR)	$1.89 Million	-1885.58%	11.01x	$8.33 Million
Synthaverse S.A. (SVE)	$30.40 Million	-106.62%	1.84x	$60.37 Million

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$106.26 Million

zł386.11 Million PLN

Market Cap Rank

#19053 Global

#147 in Poland

Share Price

zł16.70

Change (1 day)

-1.65%

52-Week Range

zł13.76 - zł29.90

All Time High

zł75.00